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Hong Kong, Malaysia, Vietnam, Singapore and Japan)
has a large and ageing population with a high prevalence
of infectious and chronic disease and demand for phar-
maceuticals. Until recently Asia has been placed at the
top of every multinational pharmaceutical company’s list
of investment priorities and there has been growing inter-
est in the economic evaluation of pharmaceuticals. The
aim of this study is to examine recent developments and
the potential for pharmacoeconomics in Asia in the con-
text of financial economies, recent health reforms, regu-
lation, registration and reimbursement, the conduct of
clinical trials, and the availability of health economics ex-
pertise. METHODS: A systematic review involving data-
bases (MEDLINE, HEED, NHS EED) and hand-searches
of journals was conducted for economic evaluations orig-
inating in Asian countries to-date, and each identified
economic evaluation was then assessed for quality using
a modified checklist based on Drummond et al. (1997).
Simultaneously, multivariate techniques were used to ex-
plore relationships and trends between data on key eco-
nomic and health indicators, healthcare expenditures,
market sizes and epidemiological statistics of countries
within the Asian region. In addition membership lists
(e.g. iHEA, APHEN, ISTAHC, HESG) were scanned to
gauge approximate numbers of health economists operat-
ing within the region. Finally a review of the literature
supported by personal interviews was performed to de-
rive information on the nature of the health care environ-
ments and commercial operating conditions within the
region to set the results in context. RESULTS: Few eco-
nomic evaluations have been conducted in the Asian re-
gion to date (China  9, South Korea  2, Taiwan  6,
the Philippines  6, Indonesia  4, Thailand  32, Hong
Kong  16, Malaysia  4, Vietnam  3 and Singapore 
14 and Japan  31) covering a multitude of clinical ar-
eas. The majority of economic evaluations were cost-con-
sequence analyses and varied in quality. Very few eco-
nomic evaluations were commissioned by industry. As in
Europe, Asian countries differ widely in their methods of
healthcare financing, regulation and distribution and
their approaches to the pricing and reimbursement of
pharmaceuticals. Generally clinical trials conducted in
the Asian region tend to be small-scale studies as most
Asian countries accept the validity of well-controlled tri-
als elsewhere, which has implications for economic eval-
uation study design. No official guidance for the conduct
of economic evaluations exists for any of the countries in
Asia to date. Diseases common in the West such as Type
II diabetes, ischaemic heart disease, stroke, cancer, respi-
ratory illnesses, asthma, osteoporosis, and arthritis are
becoming increasingly prevalent in Asia and depression,
alcoholism and suicide are growing problems. CON-
CLUSIONS: Worldwide, economic evaluations are gen-
erating huge interest as new financial pressures are placed
on governments. Rapid healthcare reform is occurring
throughout the Asian region and it is likely that in the fu-
ture, pharmaceutical companies have to be far more ac-
countable for their products. Population numbers alone
dictate that Asia will evolve into the world’s biggest pur-
chasers of medicines, but at some point decision-makers
in the Asian region will require assessments of the costs
and benefits of pharmaceuticals. Up to now economic
evaluation is not well developed in Asia and much work
needs to be done. This research offers some insights for
pharmaceutical companies looking to develop strategies
for the economic evaluation of pharmaceuticals in Asia.
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Treatment of chronic illness represents significant cost,
accounting for approximately 75% of US health care ex-
penditures. These costs will likely increase as the US pop-
ulation ages. OBJECTIVE: To determine the total and
component costs in patients with one, and two concur-
rent chronic illnesses. METHODS: Data from 284,060
Oklahoma Medicaid patients from fiscal year 1995 com-
prised the study universe. Patients were classified into 23
chronic disease states by diagnosis and prescription drug-
disease evidence. The nine most prevalent chronic ill-
nesses were: psychosis, depression, cardiovascular illness,
congestive heart failure, diabetes, stomach illness, respi-
ratory illness/asthma, hypertension and anxiety. RE-
SULTS: As single illnesses, there were three levels of
yearly spending by ANOVA. Psychosis and depression
were the highest with costs of $6964 and $5505, respec-
tively. The next highest cost group ranged from $2320 to
$1634 and was composed of cardiovascular illness, con-
gestive heart failure, diabetes, stomach illness, and respi-
ratory illness. The low cost illnesses were hypertension
and anxiety with costs of $1351 and $1334, respectively.
MANOVA was employed to determine significant com-
ponent costs. Psychosis and depression utilized primarily
psychologist and hospital, respectively. Moderate cost
diseases utilized hospital most, then pharmacy. Low cost
illnesses used pharmacy and hospital equally. Two-
disease combinations displayed three levels of spending.
High, moderate and low cost single illnesses formed high,
moderate and low cost pairs, respectively. The psychosis
and depression pair was the highest cost of all pairs, with
total costs of $18,316. This represented a statistical inter-
action on cost. CONCLUSION: Supra-additive effects on
total and component costs were found in selected two-
disease combinations.
